Post-transplant lymphoproliferative disorder following renal transplantation: A single-center experience over 40 years

被引:22
作者
Abe, Toyofumi [1 ]
Ichimaru, Naotsugu [1 ]
Kokado, Yukito [2 ]
Maeda, Tetsuo [3 ]
Kakuta, Yoichi [1 ]
Okumi, Masayoshi [1 ]
Imamura, Ryoichi [1 ]
Nonomura, Norio [1 ]
Isaka, Yoshitaka [4 ]
Takahara, Shiro [4 ]
Okuyama, Akihiko [1 ]
机构
[1] Osaka Univ, Grad Sch Med, Dept Specif Organ Regulat Urol, Suita, Osaka 5650871, Japan
[2] Takahashi Clin, Osaka, Japan
[3] Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, Suita, Osaka 5650871, Japan
[4] Osaka Univ, Grad Sch Med, Dept Adv Technol Transplantat, Suita, Osaka 5650871, Japan
关键词
malignant lymphoma; post-transplant lymphoproliferative disorder (PTLD); renal transplantation; rituximab; EPSTEIN-BARR-VIRUS; IMMUNOSUPPRESSION; KIDNEY;
D O I
10.1111/j.1442-2042.2009.02405.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To investigate post-transplant lymphoproliferative disorder (PTLD) following renal transplantation at our institution. Methods: Medical records of 631 patients who underwent renal transplantation at Osaka University Hospital between March 1965 and December 2008 were reviewed. Results: PTLD following renal transplantation was detected in 10 patients (five men, five women; mean age at transplantation, 38.5 years). Mean duration from renal transplantation to the onset of PTLD was 7.1 years (range, 5 months to 18 years, 9 months). Mean duration of observation was 3.9 years from the onset of PTLD. Immunosuppressant therapy comprised multidrug combination therapy, including cyclosporine in six patients and tacrolimus in four patients. In addition to a reduction in the immunosuppressant dose, which was performed in all patients, PTLD was treated with surgery in seven patients, radiotherapy in two patients, rituximab in five patients, and cytotoxic chemotherapy in four patients. A complete remission in eight patients and progressive disease in two were observed. At last follow up, seven patients were alive and five patients had functioning grafts. Conclusions: The incidence of PTLD following renal transplantation at our institution is 1.6% with onset occurring more than 5 years after transplantation in five patients. Consequently, with long-term renal graft survival now feasible, attention must be paid to detecting late-onset PTLD.
引用
收藏
页码:48 / 54
页数:7
相关论文
共 18 条
[1]   Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution [J].
Choquet, Sylvain ;
Oertel, Stephan ;
LeBlond, Veronique ;
Riess, Hanno ;
Varoqueaux, Nathalie ;
Doerken, Bernd ;
Trappe, Ralf .
ANNALS OF HEMATOLOGY, 2007, 86 (08) :599-607
[2]   Post-transplant lymphoproliferative disease [J].
Dharnidharka, Vikas R. ;
Araya, Carlos E. .
PEDIATRIC NEPHROLOGY, 2009, 24 (04) :731-736
[3]  
Dotti G, 2000, TRANSPLANTATION, V69, P827
[4]  
*EBPG EXP GROUP RE, 2002, NEPHROL DIAL TRAN S4, V17, P35
[5]  
EBPG Expert Group on Renal Transplantation, 2002, Nephrol Dial Transplant, V17 Suppl 4, P31
[6]   Epstein-Barr virus and post-transplant lymphoproliferative disease [J].
Holmes, RD ;
Sokol, RJ .
PEDIATRIC TRANSPLANTATION, 2002, 6 (06) :456-464
[7]   Prospective longitudinal analysis of quantitative Epstein-Barr virus polymerase chain reaction in pediatric liver transplant recipients [J].
Kogan, DL ;
Burroughs, M ;
Emre, S ;
Fishbein, T ;
Moscona, A ;
Ramson, C ;
Shneider, BL .
TRANSPLANTATION, 1999, 67 (07) :1068-1070
[8]   Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: A distinct entity? [J].
Leblond, V ;
Davi, F ;
Charlotte, F ;
Dorent, R ;
Bitker, MO ;
Sutton, L ;
Gandjbakhch, I ;
Binet, JL ;
Raphael, M .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) :2052-2059
[9]   INTERFERON-ALPHA-INDUCED ACUTE RENAL-ALLOGRAFT REJECTION [J].
MAGNONE, M ;
HOLLEY, JL ;
SHAPIRO, R ;
SCANTLEBURY, V ;
MCCAULEY, J ;
JORDAN, M ;
VIVAS, C ;
STARZL, T ;
JOHNSON, JP .
TRANSPLANTATION, 1995, 59 (07) :1068-1070
[10]  
OBrien S, 1997, J AM SOC NEPHROL, V8, P1483